Emerging Biotechs Adopt Veeva Basics for Enhanced Drug Development Processes

Standardizing Operations with Veeva Basics

In a recent announcement, Veeva Systems (NYSE: VEEV) stated that over 175 emerging biotechnology companies have laid a solid technological groundwork by implementing Veeva Basics. These burgeoning firms are able to launch pre-configured and pre-validated Veeva Basics applications within a matter of weeks, enabling them to efficiently transition from startup phases to full-scale commercialization. This adaptability is crucial for maintaining a competitive edge in the fast-paced biotech industry.

Veeva Basics facilitates the integration of comprehensive applications across various domains: clinical, regulatory, quality, medical, and commercial. This enables high-growth companies to not only speed up innovation but also optimize their resources, saving time, effort, and costs in their operations. As Bryan Ball, Chief Technology Operations Officer at Whitehawk Therapeutics, highlighted, the adoption of Veeva tools has been transformative for their processes, allowing for a faster and more compliant operational model without the need for extensive IT support or complicated customizations.

Enhancing Quality Control and Speed

In addition to accelerating processes, Veeva Basics empowers biotechs to reevaluate their operational methodologies. A significant trend is the shift in regulatory publishing strategies from outsourcing to insourcing. The introduction of Veeva Submissions Publishing Basics has provided an effective solution for submission building and health authority interactions, allowing regulatory teams to regain control over their publishing efforts. For companies preparing their inaugural submissions to the FDA, Veeva Basics has proven essential in achieving critical regulatory milestones with clearer visibility and better governance throughout the regulatory life cycle.

Darryl Clarke, Global Head of Regulatory Operations at Structure Therapeutics, acknowledged the advantages of insourcing their submission publishing. He reported marked improvements in quality control processes and significantly reduced timelines for regulatory approvals due to the capabilities provided by Veeva Basics.

A Community of Innovators

The rapid pace of innovation in biotechnology necessitates tools that keep up with their demanding operational needs. As Jim Thai, Vice President of Veeva Basics, stated, “Biotechs are responsible for so much of the innovation shaping the industry, and they need technology that reflects the pace they operate in.” Veeva’s commitment to working closely with these industry pioneers has fostered a vibrant community of Veeva Basics users who are pushing the boundaries of drug development.

The Veeva Basics applications are built upon the robust Vault Platform, ensuring that customers can effortlessly scale their technological infrastructure as they grow. Companies interested in learning more about Veeva Basics can visit veevabasics.com for additional insights and information.

Furthermore, the upcoming Veeva RD and Quality Summit, scheduled for October 20-21 in Boston, promises to be a valuable gathering for life sciences professionals to discuss advances in drug development and regulatory challenges.

For Veeva Systems, the commitment to innovation, product excellence, and customer success remains paramount. With over 1,500 customers, from industry giants to emerging biotechs, Veeva’s objective is clear: to support the initiatives that enhance life sciences and maintain a balance of interests among its diverse stakeholders. More information can be found at veeva.com.